Absolute bioavailability of imidafenacin after oral administration to healthy subjects

British Journal of Clinical Pharmacology

Volumn 65, Issue 2, 2008, Pages 197-202

  Ohno, Tomoya ^a   Nakade, Susumu ^a   Nakayama, Kazuki ^a   Kitagawa, Junsaku ^a   Ueda, Shinya ^a   Miyabe, Hiroyuki ^a   Masuda, Yuichi ^b   Miyata, Yasuyuki ^a  

^a ONO PHARMACEUTICAL CO   (Japan)

^b KYORIN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Bioavailability; Human; Intravenous; Oral; Pharmacokinetics

Indexed keywords

IMIDAFENACIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; FATIGUE; HEADACHE; HUMAN; MALE; MICELLAR LIQUID CHROMATOGRAPHY; NORMAL HUMAN; PRIORITY JOURNAL; SKIN PAIN; TANDEM MASS SPECTROMETRY;

ADMINISTRATION, ORAL; ADULT; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED;

EID: 38649129876     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2007.02999.x     Document Type: Article

References (9)

1. Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, Van Kerrebroeck P, Victor A, Wein A. The standardization of terminology in lower urinary tract function: report from the standardization sub-committee of the international continence society. Urology 2003 61 : 37 49.
2. Jackson S. The patient with an overactive bladder-symptoms and quality of life issues. Urology 1997 50 : 18 24.
3. Liberman JN, Hunt TL, Stewart WF, Wein A, Zhou Z, Herzog AR, Lipton RB, Diokno AC. Health-related quality of life among adults with symptoms of overactive bladder: results from a US community-based survey. Urology 2001 57 : 1044 50.
4. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, Hunt TL, Wein AJ. Prevalence and burden of overactive bladder in the United States. World J Urol 2003 20 : 327 36.
5. Margalith I, Gillon G, Gordon D. Urinary incontinence in women under 65: quality of life, stress related to incontinence and patterns of seeking health care. Qual Life Res 2004 13 : 1381 90.
6. Hu TW, Wagner TH, Bentkover JD, Leblanc K, Piancentini A, Stewart WF, Corey R, Zhou SZ, Hunt TL. Estimated economic costs of overactive bladder in the United States. Urology 2003 61 : 1123 8.
7. Wein AJ, Rovner ES. The overactive bladder: an overview for primary care health providers. Int J Fertil Womens Med 1999 44 : 56 66.
8. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993 10 : 1093 5.
9. 14C] Imidafenacin, a new compound for treatment of overactive bladder following oral administration to healthy male subjects. Drug Metab Oispos 2007. Epub ahead of print doi:10.1124/dmd.107.016030.